Asosiy kontentga oʻtish
Maqola

Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis

Victoria BrownMDS Pharma Services, Montreal, CanadaKetan PatelDepartment of Family Practice, University of Michigan Medical SchoolMaria ViskadurakiChemoprevention Agent Development Research Group, National Cancer Institute, Bethesda, MarylandJames A. CrowellAuthors' Affiliations: 1Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom; 2Chemoprevention Agent Development Research Group, National Cancer Institute, Bethesda, Maryland; 3Pharmascience, Inc.; 4MDS Pharma Services, Montreal, Canada; 5Department of Family Practice, University of Michigan Medical School; and 6Departments of Internal Medicine and Pharmacology, University of Michigan Medical School and VA Medical Center, Ann Arbor, MichiganMarjorie PerloffPharmascience, IncTristan D. BoothPharmascience, IncGrygoriy VasilininAuthors' Affiliations: 1Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom; 2Chemoprevention Agent Development Research Group, National Cancer Institute, Bethesda, Maryland; 3Pharmascience, Inc.; 4MDS Pharma Services, Montreal, Canada; 5Department of Family Practice, University of Michigan Medical School; and 6Departments of Internal Medicine and Pharmacology, University of Michigan Medical School and VA Medical Center, Ann Arbor, MichiganAnanda SenPharmascience, IncAnna Maria SchinasDepartment of Family Practice, University of Michigan Medical SchoolGianfranca PiccirilliAuthors' Affiliations: 1Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom; 2Chemoprevention Agent Development Research Group, National Cancer Institute, Bethesda, Maryland; 3Pharmascience, Inc.; 4MDS Pharma Services, Montreal, Canada; 5Department of Family Practice, University of Michigan Medical School; and 6Departments of Internal Medicine and Pharmacology, University of Michigan Medical School and VA Medical Center, Ann Arbor, MichiganKaren BrownAuthors' Affiliations: 1Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom; 2Chemoprevention Agent Development Research Group, National Cancer Institute, Bethesda, Maryland; 3Pharmascience, Inc.; 4MDS Pharma Services, Montreal, Canada; 5Department of Family Practice, University of Michigan Medical School; and 6Departments of Internal Medicine and Pharmacology, University of Michigan Medical School and VA Medical Center, Ann Arbor, MichiganWilliam P. StewardChemoprevention Agent Development Research Group, National Cancer Institute, Bethesda, MarylandAndreas J. GescherChemoprevention Agent Development Research Group, National Cancer Institute, Bethesda, MarylandDean E. BrennerMDS Pharma Services, Montreal, Canada
2010en
ABI

Annotatsiya

Resveratrol, a naturally occurring polyphenol, has cancer chemopreventive properties in preclinical models. It has been shown to downregulate the levels of insulin-like growth factor-1 (IGF-I) in rodents. The purpose of the study was to assess its safety, pharmacokinetics, and effects on circulating levels of IGF-I and IGF-binding protein-3 (IGFBP-3) after repeated dosing. Forty healthy volunteers ingested resveratrol at 0.5, 1.0, 2.5, or 5.0 g daily for 29 days. Levels of resveratrol and its metabolites were measured by high performance liquid chromatography-UV in plasma obtained before and up to 24 hours after a dose between days 21 and 28. IGF-I and IGFBP-3 were measured by ELISA in plasma taken predosing and on day 29. Resveratrol was safe, but the 2.5 and 5 g doses caused mild to moderate gastrointestinal symptoms. Resveratrol-3-O-sulfate, resveratrol-4'-O-glucuronide, and resveratrol-3-O-glucuronide were major plasma metabolites. Maximal plasma levels and areas under the concentration versus time curve for the metabolites dramatically exceeded those for resveratrol, in the case of areas under the concentration versus time curve, by up to 20.3-fold. Compared with predosing values, the ingestion of resveratrol caused a decrease in circulating IGF-I and IGFBP-3 (P<0.04 for both), respectively, in all volunteers. The decrease was most marked at the 2.5 g dose level. The results suggest that repeated administration of high doses of resveratrol generates micromolar concentrations of parent and much higher levels of glucuronide and sulfate conjugates in the plasma. The observed decrease in circulating IGF-I and IGFBP-3 might contribute to cancer chemopreventive activity.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba